Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
(Cancer Sci 2010; 101: 586–593) The glycan molecules that preferentially appear in cancers are clinically utilized as serum tumor markers. The exact reason, however, why glycans are useful as tumor markers remain elusive. Here, we will summarize lessons learned from well‐established cancer‐associated glycans, and propose strategies to develop new cancer markers. Our recent results on cancer‐associated glycans, sialyl Lewis A and sialyl Lewis X, indicated that the repressed transcription of some glycan genes by epigenetic silencing during early carcinogenesis, and the transcriptional induction of some other glycan genes by tumor hypoxia accompanying cancer progression at locally advanced stages, are two major factors determining cancer‐associated glycan expression. Multiple genes are involved in glycan synthesis, and epigenetic silencing of a part of such genes leads to accumulation of glycans having truncated incomplete structures, which are readily detected by specific antibodies. Glycans are very unique and advantageous as marker molecules because they are capable of reflecting epigenetic silencing in their structures. Transcriptional induction of some glycan genes by tumor hypoxia at the later stages produces further glycan modifications, such as an unusual increase of the N‐glycolyl sialic acid residues in the glycan molecules. The entire process of malignant transformation thus creates abnormal glycans, whose structures reveal the effects of both epigenetic silencing and tumor hypoxia. The second advantage of a glycan marker over a proteinous marker is that they can reflect the plurality of genetic anomalies in a singular molecule, as it is synthesized by the cooperative action of multiple genes. Glycans are sometimes covalently bound to well‐known cancer‐associated proteins, such as CD44v, and this eventually contributes to a high cancer specificity and functional relevancy in cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell metabolism by hypoxia-inducible factor 1
Semenza, G. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.009 · Cited by 469
SHAP Potentiates the CD44-mediated Leukocyte Adhesion to the Hyaluronan Substratum
Zhuo, L., Kanamori, A., Kannagi, R., Itano, N., Wu, J., Hamaguchi, M., Ishiguro, N., & Kimata, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506703200 · Cited by 150
Self-citation
Cited by
Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594
“Hypoxic conditions often found in tumors might alter expression of glycosyltransferases (Kannagi et al., 2010), including sialyltransferases such as ST6GalNAcI to create sialyl-Tn antigens.”
BackgroundRoles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Jandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65899 · Cited by 439
Altered Tumor-Cell Glycosylation Promotes Metastasis
Häuselmann, I., & Borsig, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00028 · Cited by 382
Phenylboronic Acid-Installed Polymeric Micelles for Targeting Sialylated Epitopes in Solid Tumors
Deshayes, S., Cabral, H., Ishii, T., Miura, Y., Kobayashi, S., Yamashita, T., Matsumoto, A., Miyahara, Y., Nishiyama, N., & Kataoka, K. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406406h · Cited by 348
Metadata
- Authors
- Kannagi, R., Sakuma, K., Miyazaki, K., Lim, K., Yusa, A., Yin, J., & Izawa, M.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2010-02-17
- Volume
- 101
- Issue
- 3
- Pages
- 586-593
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2005272275
- Cited by
- 91
- References
- 2
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.